v3.7.0.1

CONDENSED BALANCE SHEETS - USD ($)	Jan. 31, 2017	Oct. 31, 2016
Current Assets
Cash and cash equivalents
Interest receivable from NewGen BioPharma Corporation (New Jersey)	1,356
Loans receivable from NewGen BioPharma Corporation (New Jersey)	200,000
Total Current Assets	201,356
TOTAL ASSETS	201,356
Current Liabilities
Accounts payable and accrued liabilities	124,550	30,800
Loans payable to former (to February 8, 2017) sole director and Chief Executive Officer	105,452	94,376
Total Liabilities	230,002	125,176
Stockholders' Deficit
Common stock, par $0.001, 300,000,000 shares authorized, 47,850,000 and 47,600,000 shares issued and outstanding at January 31, 2017 and October 31, 2016, respectively (including 250,000 shares at January 31, 2017 subscribed to and paid for but not yet issued)	47,850	47,600
Additional paid in capital	267,527	17,777
Accumulated deficit	(344,023)	(190,553)
Total Stockholders' Deficit	(28,646)	(125,176)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 201,356

The aggregate of amounts due from customers or clients, within one year of the balance sheet date (or one operating cycle, if longer), for goods or services that have been delivered or sold in the normal course of business and an amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date within one year of the balance sheet, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection and net of any write-downs taken for collection uncertainty on the part of the holder, respectively.

NewGen BioPharma Corp. 10-Q